Today: 14 January 2026
Subscribe
Browse Category

Investment Analysis News 13 December 2025 - 14 December 2025

City Developments (CDL) Stock Update: SGX:C09 Rises on Bullish Broker Calls, Asset Recycling Focus — Outlook for This Week and Week Ahead (Updated 14 Dec 2025)

City Developments (CDL) Stock Update: SGX:C09 Rises on Bullish Broker Calls, Asset Recycling Focus — Outlook for This Week and Week Ahead (Updated 14 Dec 2025)

City Developments Limited (CDL) shares ended the latest trading week higher after a fresh wave of bullish sell-side commentary lifted sentiment across Singapore property developers. CDL’s stock (SGX: C09) last closed at S$7.34 on Friday, 12 Dec 2025, up 1.8%
14 December 2025
···
South32 Ltd (ASX: S32) Stock: Buyback Shrinks Share Count, Hermosa Water Probe Grabs Headlines, and What to Watch This Week (Updated 14 Dec 2025)

South32 Ltd (ASX: S32) Stock: Buyback Shrinks Share Count, Hermosa Water Probe Grabs Headlines, and What to Watch This Week (Updated 14 Dec 2025)

South32 Ltd stock (ASX: S32) heads into the new trading week with a busy mix of catalysts: an ongoing on‑market share buyback, a newly completed divestment in Colombia, boardroom changes, and fresh scrutiny around the company’s Hermosa project in Arizona.
14 December 2025
····
Destiny Tech100 (DXYZ) Stock Surges on SpaceX IPO Buzz: What Happened This Week, Premium-to-NAV Reality Check, and Week-Ahead Watchlist (Updated Dec. 12, 2025)

Destiny Tech100 (DXYZ) Stock Surges on SpaceX IPO Buzz: What Happened This Week, Premium-to-NAV Reality Check, and Week-Ahead Watchlist (Updated Dec. 12, 2025)

Updated: Dec. 12, 2025 (U.S. market close). Destiny Tech100 Inc. (NYSE: DXYZ) just posted a sharp, high-volume run-up as investor attention snapped back to one theme: SpaceX IPO speculation—and what it could mean for public-market “access” vehicles tied to private
14 December 2025
····
Milestone Pharmaceuticals (MIST) Stock Update: FDA Approves CARDAMYST (Etripamil) — This Week’s Volatility, Analyst Forecasts, and What to Watch Next (Updated Dec. 12, 2025)

Milestone Pharmaceuticals (MIST) Stock Update: FDA Approves CARDAMYST (Etripamil) — This Week’s Volatility, Analyst Forecasts, and What to Watch Next (Updated Dec. 12, 2025)

Updated: Friday, December 12, 2025 (U.S. market close) Milestone Pharmaceuticals Inc. (NASDAQ: MIST) closed out the week in the spotlight after the company announced U.S. FDA approval of CARDAMYST™ (etripamil)—positioning Milestone to transition from a development-stage biotech to a commercial-stage
14 December 2025
····
HCA Stock Outlook: HCA Healthcare (NYSE: HCA) Ends the Week Near $485 After a Volatile Swing — Latest News, Forecasts, and the Week Ahead (Updated Dec. 12, 2025)

HCA Stock Outlook: HCA Healthcare (NYSE: HCA) Ends the Week Near $485 After a Volatile Swing — Latest News, Forecasts, and the Week Ahead (Updated Dec. 12, 2025)

Updated: December 12, 2025 (U.S. market close)HCA Healthcare, Inc. (NYSE: HCA) closed Friday at $484.77, finishing the week essentially flat—but not quiet. A sharp midweek drop and quick rebound put policy risk, reimbursement headlines, and year-end positioning back in the
13 December 2025
····
1 … 114 115 116 117 118 … 231
Go toTop